

IBA Notice of Half Year 2021 Results and Conference Call

HY21 Results Conference Call to take place on Wednesday, 25 August 2021 at 3pm CEST

Louvain-Ia-Neuve, Belgium, 10 August 2021 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, announces today that it will publish its consolidated results for the half year 2021 on Wednesday, 25 August 2021 at 7am CEST.

Conference Call Information

In addition to the press release, Olivier Legrain, Chief Executive Officer, and Soumya Chandramouli, Chief Financial Officer, will host a conference call and webcast, conducted in English, to present the half year results, followed by a Q&A session.

This conference call will be held on **Wednesday**, **25** August **2021** at **3pm CEST / 2pm BST / 9am EDT / 6am PDT** as a Teams webinar and can be accessed <u>online on this link</u>. If you would like to join by phone only, please dial (Phone conference ID 646 384 377#):

Belgium:	+32 2 890 97 20
UK:	+44 20 3321 5200
NL:	+31 20 708 6901
LU:	+352 27 87 00 02
US:	+1 347-991-7591
FR:	+33 1 70 99 53 51

The presentation will be available on <u>IBA's investor relations</u> website and on: <u>https://www.iba-worldwide.com/content/half-year-2021-results-press-release-and-web-conference</u> shortly before the call.

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

For participants who do not have the Teams application installed, please follow the process described in <u>this link</u> to access the conference.

ENDS

Press release | August 10, 2021



IBA | Ion Beam Applications SA Chemin du Cyclotron, 3 | 1348 Louvain-la-Neuve | Belgium | RPM Brabant-wallon VAT : 0428.750.985 | T +32 10 47 58 11 | F +32 10 47 58 10 info@iba-group.com | iba-worldwide.com



1



About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,500 people worldwide.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

CONTACTS

Soumya Chandramouli Chief Financial Officer +32 10 475 890 Investorrelations@iba-group.com

Olivier Lechien Corporate Communication Director +32 10 475 890 communication@iba-group.com

Consilium Strategic Communications

Amber Fennell, Angela Gray, Lucy Featherstone +44 (0) 20 3709 5700 IBA@consilium-comms.com

Press release | August 10, 2021



